High Quality Octreotide Acetate for Health Care CAS 83150-76-9 CAS NO.83150-76-9

1. Hubei Jusheng Technology Co., Ltd.,  is a global chemical industry manufacturers and suppliers of pharmaceuticals and intermediates in China.

2. The yearly production capacity is 50000MT, 80% for export.We have a professinal export team. Both by Air and by Sea,we ensure that we meet the customer expectations with promptness.
3. Our company facing global High-tech pharmaceutical raw materials, high complex new type intermediates, fine chemicals custom synthesis, scale-up production and Rare chemicals trade. Corey have well-equipped machine, strong technical force and considerate marketing team service.
4. We also have rich experience advantage in basic research, small scale process development, scale-up, industrial technology development & production and cost control.  

1. Quick Details:

Product Name: Octreotide Acetate
CAS No.: 83150-76-9
Purity (HPLC): 98.0%min.
Molecular Formula: C49H66N10O10S2
Molecular Weight: 1019.28
Appearance: White powder
Single Impurity (HPLC): 1.0%max
Amino Acid Composition: ± 10% of theoretical
Peptide Content (N%): ≥ 80.0%
Water Content(Karl Fischer): ≤ 7.0%
Acetate Content(HPIC): ≤ 12.0%
Specific Rotation (20/D): -45.0~-50.0° (c=0.5 95%HAc)
MS (ESI): Consistent
Mass Balance: 95.0~105.0%
Grade: Pharmaceutical Grade
Storage: Closed, below 2 ~ 8º C preservation
Usage: Octreotide acetate, as an injectable depot formulation for the treatment of producing tumors (acromegaly and gigantism).

2. Description:

Octreotide Acetate (brand name Sandostatin, Novartis Pharmaceuticals) is an octapeptide that mimics natural somatostatin pharmacologically, though Octreotide Acetate is a more potent inhibitor of , glucagon, and insulin than the natural hormone. Octreotide Acetate was first synthesized in 1979 by the chemist Wilfried Bauer.

3. Application:

Octreotide Acetate has also been used off-label for the treatment of severe, refractory diarrhea from other causes. Octreotide Acetate is used in toxicology for the treatment of prolonged recurrent hypoglycemia after sulfonylurea and possibly meglitinides overdose. Octreotide Acetate has also been used with varying degrees of success in infants with nesidioblastosis to help decrease insulin hypersecretion.
Octreotide has been used experimentally to treat obesity, particularly obesity caused by lesions in the hunger and satiety centers of the hypothalamus, a region of the brain central to the regulation of food intake and energy expenditure. The circuit begins with an area of the hypothalamus, the arcuate nucleus, that has outputs to the lateral hypothalamus (LH) and ventromedial hypothalamus (VMH), the brain's feeding and satiety centers, respectively. ] The VMH is sometimes injured by ongoing treatment for acute lymphoblastic leukemia (ALL) or surgery or radiation to treat posterior cranial fossa tumors.